By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Venus MedTech (HangZhou) Inc. 

Room 201, Shuiyou Building,
No.3738, Nanhuan Road, Binjiang District
Hangzhou  Zhejiang    China
Phone: 0571-87772183 Fax: 0571-87772179


Venus MedTech (HangZhou) Inc. is located in Hangzhou National High-tech Industrial Development Zone (Binjiang), with its products positioned in the development and industrialization of international advanced interventional artificial cardiac valve system, filling up the blank in China.

Interventional artificial aortic valve products researched and developed by the company takes the lead in finishing clinical tests in China. In reference to the development and promotion conditions of coronary stents at home and abroad, interventional artificial cardiac valve, as a revolutionary treatment means, has been increasingly recognized by experts, and will take on an explosible increase of clinical needs in the foreseeable next few years.




All Products

Key Statistics

Ownership: Private

Web Site: Venus MedTech

Medical Device

Company News
Venus MedTech Acquires U.S. Company InterValve To Create A Systematic TAVR Treatment And Strengthen Global Expansion 6/14/2017 8:42:07 AM
CFDA Approves Venus MedTech's Minimally Invasive Aortic Valve Implant 5/1/2017 12:37:04 PM
Venus MedTech's TAVR Device Is Approved By CFDA, Creating A New Era Of Interventional Cardiology In China 4/28/2017 8:55:59 AM
Hangzhou's Venus MedTech Forms CV Device Partnership With Keystone Heart 3/6/2017 11:22:35 AM
Keystone Heart And Venus MedTech Announce Partnership For Cerebral Embolic Protection With Transcatheter Heart Valve Systems (TAVR) In China And Key Asian Markets 3/2/2017 7:20:19 AM
The Successful Worldwide First In Human Implantation Of An Innovative Aortic Valve From Colibri Heart Valve, LLC And Venus MedTech With Disruptive "Dry Tissue" Technology Conducted 10/28/2016 7:34:28 AM
Venus MedTech's Transcatheter Pulmonary Valve Debuts In Europe, Marking The Start Of Global Clinical Trial 9/19/2016 9:02:58 AM